HPV

Merck Faces $200 Million Hit from Tariffs as Gardasil Sales Decline

1 month ago

In a challenging turn of events for Merck & Co., the pharmaceutical giant is bracing for an anticipated $200 million financial impact due to new tariffs that are significantly affecting the sales of its cervical cancer vaccine, Gardasil. This downturn in revenue comes as global sales of the vaccine have dropped drastically, placing further pressure on the company’s financial outlook.

Chinese HPV Vaccines Disrupt Merck's Gardasil Success: A Market in Turmoil

1 month ago

In a significant development within the pharmaceutical industry, the increasing availability of affordable Chinese human papillomavirus (HPV) vaccines is casting a shadow over Merck's Gardasil, which has long been considered the gold standard in HPV prevention. The recent entry of these lower-cost alternatives into the market is driving a seismic shift, turning what was once a booming sales trend for Gardasil into a concerning downturn.

Merck Suspends Gardasil Sales in China, Influencing 2025 Financial Projections

4 months ago

In a significant move that has sent ripples through the pharmaceutical industry, Merck & Co. has announced the cessation of sales for its Gardasil vaccine in China. This decision has far-reaching implications for the company's financial outlook for 2025, as China has been a pivotal market for the HPV vaccine.

Merck Adjusts Sales Forecast Amid Slowing Demand for Gardasil Vaccine in China

7 months ago

In a recent update, Merck & Co. has revised its sales outlook downward, largely attributed to subpar demand for its Gardasil vaccine in the Chinese market. The pharmaceutical giant is now bracing for a potential decline in sales as the uptake of their human papillomavirus (HPV) vaccine fails to meet projections.